查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1925859

免疫肿瘤服务市场（依治疗方法、癌症适应症、最终用户和通路划分）－2026年至2032年全球预测

Immuno-Oncology Service Market by Therapy Type, Cancer Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，免疫肿瘤服务市场价值将达到 467.7 亿美元，到 2026 年将成长至 502.3 亿美元，到 2032 年将达到 786.2 亿美元，复合年增长率为 7.70%。

关键市场统计数据
基准年 2025 467.7亿美元
预计年份：2026年 502.3亿美元
预测年份 2032 786.2亿美元
复合年增长率 (%) 7.70%

将科学进展、监管环境和商业性需求整合起来，形成对现代免疫肿瘤学格局的连贯策略概述。

免疫肿瘤学领域正处于一个转折点，科学进步、监管变革和商业性压力交织在一起，重新定义了癌症疗法的发现、开发和应用方式。免疫调节剂、细胞疗法和精准疫苗的最新进展正在拓展血液肿瘤和固态肿瘤的治疗可能性，而对肿瘤生物学和宿主免疫的日益深入的理解也在重塑临床策略。同时，医疗系统、付款者和患者都要求获得更清晰的疗效持久性、可控毒性和成本效益的证据，这促使申办方采用更全面的证据路径。

科学突破、製造创新和监管调整共同揭示了重塑免疫肿瘤学研发和治疗的新趋势

免疫肿瘤学正经历一场变革，这场变革的驱动力来自于技术创新、策略合作以及贯穿整个研发生命週期的系统性调整。细胞工程和新一代查核点调控技术的进步，正在拓展治疗的可能性，使其超越传统的单一疗法，从而实现个人化的多模态治疗方法，旨在克服抗药性机制并深化临床疗效。同时，日益成熟的伴随诊断和新抗原识别平台，能够实现更精准的患者分层，简化临床试验流程，并提高获得具有临床意义结果的可能性。

评估2025年关税调整对专业供应链、製造地地点和临床开发计画的营运和策略影响

2025年美国关税政策的变化为全球生物製药供应链引入了新的变数。这些变化对免疫肿瘤领域的相关人员影响尤其显着，因为该领域高度依赖专业原料、低温运输物流和跨境生产伙伴关係。试剂、一次性耗材和设备的关税调整直接推高了采购成本，迫使申办者和契约製造製造商重新评估筹资策略和库存管理政策。这些变化凸显了多元化供应商网路和近岸外包方案的重要性，这些方案有助于降低跨境关税和物流中断的风险，同时确保产品品质和合规性。

揭示治疗方法、临床适应症、临床环境和通路之间相互依存的细分动态，以帮助制定有针对性的开发和商业化策略。

细分市场分析揭示了治疗方法、癌症适应症、终端用户和分销管道如何影响免疫肿瘤价值链中的策略重点和营运执行。在治疗方法模式方面，以癌症疫苗为重点的研究包括基于细胞、基因和胜肽的疗法，每种疗法都有不同的研发週期和生产要求。基于细胞的疫苗需要个人化的生产流程，而基因疫苗则依赖核酸递送平台和低温运输优化。同时，基于胜肽的疗法具有标准化生产的优势，可以加速临床试验。嵌合体抗原受体T细胞疗法包括标靶BCMA和标靶CD19的构建体，它们针对不同的骨髓恶性肿瘤，因此需要个人化的试验设计、安全性监测和长期追踪通讯协定。查核点抑制剂项目因作用机製而异，CTLA-4、PD-1和PD-L1抑制剂各自具有不同的安全性特征和合併用药机会。此外，单株抗体策略（嵌合体、全人源抗体、人源化抗体）在免疫抗原性风险、生产复杂性和商业可行性方面各不相同。

绘製区域基础设施、监管差异和报销框架如何影响临床应用和商业化选择。

区域趋势反映了医疗基础设施、报销环境和临床试验生态系统的差异，这些差异在塑造免疫肿瘤产品的研究重点、监管策略和商业化路径方面发挥着至关重要的作用。在美洲，学术研究机构的集中、完善的报销机制以及经验丰富的合约研发生产机构（CDMO）共同支持复杂的临床研究设计和早期商业化试点，从而有利于临床开发。在欧洲、中东和非洲，不同的监管和支付者环境需要跨国协调、国家层级的卫生技术评估（HTA）参与以及适应性定价策略。这有助于应对不同的准入途径并有效率地进行多中心试验。在亚太地区，对生物技术生态系统的快速投资、不断扩大的临床试验能力以及对本地化生产的日益重视正在改变该地区的产品上市时间表。这为加速规模化生产并满足当地监管要求创造了伙伴关係机会。

明确构成高效组织的策略能力和协作模式，并加速临床和商业性发展进程。

免疫肿瘤领域主要企业的策略要务趋于一致，这为理解竞争行为和伙伴关係模式提供了重要线索。市场领导优先考虑平台扩充性，投资于模组化技术，以实现标靶和适应症的快速部署，同时利用共用的生产和监管途径。这些机构还优先考虑强大的转化医学能力，将早期生物标记讯号转化为适应性试验设计和伴随诊断策略。致力于细胞和基因疗法的公司往往会在生产规模化、品质体系和商业物流方面投入大量资金，以满足上市及上市后的需求。同时，专注于抗体或胜肽类疗法的公司则透过投资新的作用机制、联合疗法和更佳的安全性来寻求差异化优势。

为领导者提供切实可行的、优先排序的行动步骤，以整合创新、製造韧性和以支付方为中心的证据生成，从而实现永续的商业化。

产业领导者应优先考虑整合科学差异化、营运扩充性和与支付方合作的综合方法，以将临床潜力转化为永续的患者获益。首先，他们需要投资于平台策略和转化能力，以实现快速标靶检验、生物标记指导的队列选择和适应性试验设计，从而降低研发的不确定性。同时，他们应建立或确保冗余的生产能力，以降低个人化药物和细胞疗法的供应风险，并发展区域伙伴关係，以降低关税和物流风险，同时加快给药速度。这些营运投资应与证据生成计划保持一致，该计划应融合随机试验和真实世界数据，以支持对支付方和医疗系统的价值提案。

我们透明、多方面的调查方法，包括相关人员访谈、监管审查和情境分析，为可操作的策略建议提供支援。

本报告的调查方法结合了定性和定量方法，以确保对免疫肿瘤学生态系统提供全面可靠的见解。主要研究包括对生物技术和製药公司、临床机构、契约製造机构和专科治疗中心的高阶主管进行结构化访谈和讨论，以揭示营运限制、应用驱动因素和策略重点。次要研究整合了同行评审文献、监管指导文件、上市公司资讯披露、临床试验註册资讯和行业会议资料，以阐明趋势并检验主要研究结果。在整个研究过程中，我们运用了资料三角测量和交叉检验，以协调不同的观点，并确保建议反映出趋同的证据。

以科学、营运和准入为中心的综合规划整合了策略要务，这些要务将决定哪些创新能够取得临床和商业性的成功。

总之，免疫肿瘤学正处于一个转折点，营运上的创新和以市场为导向的证据策略对于将科学创新转化为持续的患者获益至关重要。细胞疗法、查核点调节和疫苗技术的进步创造了新的治疗机会，但要实现这些机会，需要在生产模式、区域定位和支付方参与方面做出谨慎选择。关税和供应链趋势增加了策略规划的复杂性，凸显了采购多元化和区域伙伴关係的重要性。将转化研究的重点与实际的营运投资和有针对性的商业化计画结合，能够帮助机构缩短研发週期，同时扩大病患的用药范围。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依治疗方法的免疫肿瘤服务市场

  • 癌症疫苗
    • 基于细胞
    • 基因疫苗
    • 基于胜肽的
  • CAR-T疗法
    • BCMA靶点
    • CD19标靶
  • 查核点抑制剂
    • CTLA-4抑制剂
    • PD-1抑制剂
    • PD-L1抑制剂
  • 单株抗体
    • 嵌合体体
    • 完全人类
    • 人性化

9. 依癌症适应症分類的免疫肿瘤学服务市场

  • 乳癌
  • 白血病
    • 急性淋巴性白血病
    • 急性骨髓性白血病
    • 慢性淋巴性白血病
  • 肺癌
  • 淋巴瘤
    • 何杰金氏淋巴瘤
    • 非何杰金氏淋巴瘤
  • 黑色素瘤

第十章 依最终用户分類的免疫肿瘤服务市场

  • 医院
    • 社区医院
    • 大学医院
  • 研究所
    • 学术机构
    • 政府机构
  • 专科诊所
    • 日间照顾中心
    • 肿瘤诊所

第十一章 按通路分類的免疫肿瘤服务市场

  • 直销
  • 经销商网络
    • 医疗设备批发商
    • 药品批发商
  • 线上平台
    • 公司网站
    • 第三方平台

12. 按地区分類的免疫肿瘤服务市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 按群体分類的免疫肿瘤服务市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国免疫肿瘤服务市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国免疫肿瘤服务市场

第十六章：中国肿瘤免疫服务市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • Evotec SE
  • ICON plc
  • IQVIA Holdings Inc.
  • Laboratory Corporation of America Holdings
  • Novartis AG
  • Pfizer Inc.
  • SGS SA
  • Syneos Health, Inc.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-4F7A6D4FDA88

The Immuno-Oncology Service Market was valued at USD 46.77 billion in 2025 and is projected to grow to USD 50.23 billion in 2026, with a CAGR of 7.70%, reaching USD 78.62 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 46.77 billion
Estimated Year [2026] USD 50.23 billion
Forecast Year [2032] USD 78.62 billion
CAGR (%) 7.70%

Framing the contemporary immuno-oncology landscape by integrating scientific advances, regulatory realities, and commercial imperatives into a cohesive strategic overview

The immuno-oncology field has entered a phase where scientific momentum, regulatory evolution, and commercial pressures intersect to redefine how cancer therapies are discovered, developed, and delivered. Recent advances in immune-modulating agents, cellular therapies, and precision vaccine approaches have expanded treatment possibilities across hematologic and solid tumor indications, while an increasingly sophisticated understanding of tumor biology and host immunity is reshaping clinical strategy. At the same time, health systems, payers, and patients demand clearer evidence of durable benefit, manageable toxicity, and cost-effectiveness, prompting sponsors to adopt more integrated evidence-generation pathways.

This introduction frames the report's analytical lens: we evaluate therapeutic innovation alongside practical considerations for manufacturing, distribution, and stakeholder engagement. We emphasize translational pathways from bench to bedside, mapping how pipeline differentiation, biomarker-driven patient selection, and combination strategies influence clinical development plans. The perspective balances scientific opportunity with systemic constraints, recognizing that technical feasibility must align with regulatory expectations and commercial viability. Throughout, the narrative prioritizes pragmatic insight for decision-makers seeking to position assets competitively while accelerating patient access and maintaining sustainable operations.

Charting the convergence of scientific breakthroughs, manufacturing innovation, and regulatory adaptation that is redefining immuno-oncology development and delivery

Immuno-oncology is undergoing transformative shifts driven by technological innovation, strategic collaboration, and systemic adaptation across the development lifecycle. Advancements in cell engineering and next-generation checkpoint modulation are expanding therapeutic possibilities beyond traditional single-agent approaches, enabling personalized, multi-modal regimens that aim to overcome resistance mechanisms and deepen clinical responses. Concurrently, the maturation of companion diagnostics and neoantigen identification platforms allows for more precise patient stratification, making trials more efficient and increasing the likelihood of clinically meaningful outcomes.

At the same time, manufacturing and supply chain modernization is reshaping how sponsors plan commercialization. The rise of decentralized and regionalized manufacturing models is reducing turnaround times for autologous products while allogeneic and off-the-shelf platforms are attracting investment due to their scale potential. Regulatory agencies are adapting review frameworks to accommodate complex biologics and adaptive trial designs, prompting earlier engagement between sponsors and regulators. Commercial channels are also evolving: hospitals, specialty clinics, and integrated health networks are developing centers of excellence for cell and gene therapies, which affects site selection, patient referral pathways, and reimbursement negotiations. Taken together, these shifts demand cross-functional strategies that link R&D priorities with operational capability and market access planning to realize the full potential of immuno-oncology innovations.

Assessing the operational and strategic repercussions of 2025 tariff adjustments on specialized supply chains, manufacturing placement, and clinical development planning

United States tariff policy changes in 2025 have introduced new variables into the global biopharmaceutical supply chain that disproportionately affect immuno-oncology stakeholders due to the sector's reliance on specialized raw materials, cold chain logistics, and cross-border manufacturing partnerships. Tariff adjustments on reagents, single-use consumables, and equipment can elevate direct procurement costs, forcing sponsors and contract manufacturers to reassess sourcing strategies and inventory policies. These shifts underscore the importance of diversified supplier networks and near-shoring options that reduce exposure to cross-border duties and logistical disruption while preserving quality and compliance standards.

Beyond direct cost implications, tariff dynamics influence strategic decisions around facility location, contractual terms with suppliers and distributors, and the structuring of clinical supply chains for multi-national trials. Organizations with vertically integrated manufacturing or long-term procurement agreements have greater resilience, whereas smaller entities and academic spinouts may face operational strain that could delay development timelines. In response, stakeholders are accelerating negotiations for service-level agreements, investing in tariff mitigation through alternative component specifications where feasible, and prioritizing regulatory and customs expertise in their market entry playbooks. Overall, tariff policy is prompting a recalibration of supply chain risk management and strategic planning across the immuno-oncology ecosystem.

Unpacking interdependent segmentation dynamics across therapy modalities, clinical indications, care settings, and distribution pathways to inform targeted development and commercialization strategies

Segmentation analysis highlights how therapy modality, cancer indication, end user, and distribution channel each shape strategic priorities and operational execution across the immuno-oncology value chain. Within therapy modalities, initiatives focused on cancer vaccines encompass cell-based, genetic, and peptide-based approaches, each with distinct development timelines and manufacturing requirements; cell-based vaccines demand personalized manufacturing workflows, genetic vaccines rely on nucleic acid delivery platforms and cold chain optimization, while peptide-based options offer standardized production advantages that can accelerate clinical testing. Chimeric antigen receptor T therapies include BCMA-directed and CD19-directed constructs that target different hematologic malignancies and therefore require tailored trial designs, safety monitoring, and long-term follow-up protocols. Checkpoint inhibitor programs vary by mechanism, with CTLA-4, PD-1, and PD-L1 inhibitors presenting divergent safety profiles and combination opportunities, and monoclonal antibody strategies-chimeric, fully human, and humanized-differ in immunogenicity risk, manufacturing complexity, and commercialization positioning.

Cancer indication segmentation underscores the importance of aligning modality choice with biological rationale and patient population characteristics. Breast cancer and lung cancer programs often emphasize combination regimens and biomarker enrichment to address heterogeneous tumor biology, whereas leukemia and lymphoma strategies hinge on targeted cellular therapies and hematologic-specific safety management, distinguishing protocols for acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma. End user segmentation further influences deployment choices: community hospitals and university hospitals present different referral patterns and infrastructure capabilities, academic and government research institutes shape clinical trial leadership and investigator-initiated studies, and specialty clinics such as day care centers and oncology clinics offer focused treatment pathways that can streamline outpatient administration. Distribution channel segmentation informs commercialization and patient access tactics, with direct sales demanding robust field engagement, distributor networks-both medical device and pharma distributors-offering scale and logistics expertise, and online platforms, including company websites and third-party platforms, supporting digital patient engagement and product information dissemination. Together, these interlocking segment perspectives enable sponsors to prioritize investments, design differentiated clinical programs, and craft market entry strategies tailored to modality-specific requirements and end-user capabilities.

Mapping how regional infrastructure, regulatory variation, and reimbursement frameworks across global territories influence clinical adoption and commercialization choices

Regional dynamics play a decisive role in shaping research priorities, regulatory strategy, and commercialization pathways for immuno-oncology products, reflecting differences in healthcare infrastructure, reimbursement environments, and clinical trial ecosystems. In the Americas, clinical development benefits from a concentration of academic centers, established reimbursement mechanisms, and experienced contract development and manufacturing organizations, which together support complex trial designs and early commercialization pilots. Europe, Middle East & Africa presents a heterogeneous regulatory and payer landscape where cross-border coordination, country-level HTA engagement, and adaptive pricing strategies are necessary to navigate diverse access pathways and to deploy multicenter trials efficiently. In the Asia-Pacific region, rapid investment in biotech ecosystems, expanding clinical trial capacity, and a growing emphasis on local manufacturing are shifting timelines for regional launches and creating opportunities for partnerships that accelerate scale-up while addressing local regulatory requirements.

These regional differences influence prioritization across clinical indications and modalities. Regions with concentrated centers of excellence tend to adopt advanced cellular therapies earlier, while areas with strong outpatient infrastructure may favor therapies that can be administered in specialized clinics. Reimbursement and procurement policies at the regional and national levels shape value dossiers and evidence generation plans, and logistics considerations-such as cold chain connectivity and customs facilitation-affect decisions about centralized versus decentralized manufacturing. By aligning development strategies with regional capabilities and policy realities, sponsors can optimize trial site selection, regulatory engagement, and commercial rollouts to improve patient access and implementation success.

Identifying the strategic capabilities and collaborative models that distinguish high-performing organizations and accelerate clinical and commercial momentum

A concentrated set of strategic imperatives differentiates leading companies in immuno-oncology and offers insight into competitive behaviors and partnership models. Market leaders emphasize platform extensibility, investing in modular technologies that allow rapid iteration across targets and indications while leveraging shared manufacturing and regulatory pathways. These organizations also prioritize robust translational medicine capabilities that translate early biomarker signals into adaptive trial designs and companion diagnostic strategies. Companies pursuing cellular and genetic modalities tend to invest heavily in manufacturing scale-up, quality systems, and commercial logistics to ensure readiness for launch and post-launch demand, whereas organizations focused on antibody-based or peptide-based approaches invest in differentiation through novel mechanisms of action, combination strategies, and improved safety profiles.

Across the ecosystem, strategic alliances between biotechs, academic centers, and contract service providers are accelerating capability acquisition and reducing time-to-clinic. Successful firms maintain diversified distribution strategies to balance direct engagement with institutional customers and partnerships with distributor networks that can deliver logistical and regional market knowledge. Pricing and access strategies are increasingly evidence-driven, with leading companies designing post-approval evidence generation and outcomes-based agreements to address payer concerns. Finally, operational resilience-demonstrated through supply chain redundancy, regulatory foresight, and flexible manufacturing capacity-serves as a critical competitive advantage in an industry where product complexity and patient needs demand consistently high quality and on-time delivery.

Practical and prioritized action steps for leaders to align innovation, manufacturing resilience, and payer-focused evidence generation for sustainable commercialization

Industry leaders should prioritize an integrated agenda that links scientific differentiation with operational scalability and payer engagement to convert clinical promise into sustainable patient impact. First, invest in platform strategies and translational capabilities that reduce development uncertainty by enabling rapid target validation, biomarker-driven cohort selection, and adaptive trial designs. Concurrently, build or secure manufacturing capacity with redundancy to reduce supply risk for personalized and cell-based modalities, and consider regional partnerships to mitigate tariff and logistics exposure while improving time-to-infusion. These operational investments should be synchronized with evidence generation plans that blend randomized studies with real-world data to support value narratives for payers and health systems.

Commercial strategies must be tailored to end users and regional realities: develop differentiated messaging for community and university hospital systems, engage specialty clinics to expand outpatient delivery capacity, and leverage distributor networks and digital platforms to optimize access pathways. Pursue outcome-based pricing pilots where appropriate to align value with payment and to de-risk uptake for high-cost therapies. Finally, form strategic alliances with academic centers, contract developers, and diagnostic companies to share risk, accelerate enrollment, and co-develop companion diagnostics. By executing a coordinated approach that aligns R&D, manufacturing, and market access, organizations can reduce time-to-impact while maintaining financial and operational resilience.

Transparent, multi-source research methods integrating stakeholder interviews, regulatory review, and scenario analysis to underpin actionable strategic recommendations

The research methodology underpinning the report combines qualitative and quantitative approaches to ensure comprehensive and credible insight into the immuno-oncology ecosystem. Primary research involved structured interviews and consultations with senior executives across biotech, pharmaceutical, clinical institutions, contract manufacturing organizations, and specialty treatment centers to surface operational constraints, adoption drivers, and strategic priorities. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, public company disclosures, clinical trial registries, and industry conference materials to contextualize trends and validate primary findings. Data triangulation and cross-validation were applied throughout to reconcile differing perspectives and to ensure that recommendations reflect convergent evidence.

Analytical techniques included comparative capability mapping across therapy modalities and regions, scenario analysis to assess supply chain and policy sensitivities, and thematic synthesis to identify emerging best practices in evidence generation and commercialization. Expert review panels provided iterative feedback on draft findings, enhancing practical relevance and ensuring that strategic recommendations are actionable for stakeholders across development, manufacturing, and commercial functions. The methodology emphasizes transparency and reproducibility, documenting assumptions, data sources, and interview frameworks to enable stakeholders to adapt insights to their specific contexts.

Synthesis of strategic imperatives showing how integrated scientific, operational, and access-focused planning will determine which innovations achieve clinical and commercial success

In conclusion, immuno-oncology stands at an inflection point where scientific innovation must be matched by operational ingenuity and market-oriented evidence strategies to achieve durable patient impact. Advances in cellular therapies, checkpoint modulation, and vaccine technologies create new therapeutic opportunities, but realizing those opportunities requires deliberate choices about manufacturing models, regional positioning, and payer engagement. Tariff and supply chain dynamics add complexity to strategic planning, increasing the importance of diversified sourcing and regional partnerships. By aligning translational research priorities with pragmatic operational investments and targeted commercialization plans, organizations can both shorten development cycles and support broader patient access.

Moving forward, success will accrue to those who build platform flexibility, invest in translational and regulatory expertise, and cultivate collaborative partnerships that share risk and accelerate learning. Operational resilience and evidence-based access strategies will determine which innovations move from promising science to routine clinical practice. The overarching message is that integrated planning across scientific, regulatory, operational, and commercial functions is the critical enabler for durable success in the evolving immuno-oncology landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Immuno-Oncology Service Market, by Therapy Type

  • 8.1. Cancer Vaccines
    • 8.1.1. Cell Based
    • 8.1.2. Genetic Vaccines
    • 8.1.3. Peptide Based
  • 8.2. Car-T Therapy
    • 8.2.1. Bcma Directed
    • 8.2.2. Cd19 Directed
  • 8.3. Checkpoint Inhibitors
    • 8.3.1. Ctla-4 Inhibitors
    • 8.3.2. Pd-1 Inhibitors
    • 8.3.3. Pd-L1 Inhibitors
  • 8.4. Monoclonal Antibodies
    • 8.4.1. Chimeric
    • 8.4.2. Fully Human
    • 8.4.3. Humanized

9. Immuno-Oncology Service Market, by Cancer Indication

  • 9.1. Breast Cancer
  • 9.2. Leukemia
    • 9.2.1. Acute Lymphoblastic Leukemia
    • 9.2.2. Acute Myeloid Leukemia
    • 9.2.3. Chronic Lymphocytic Leukemia
  • 9.3. Lung Cancer
  • 9.4. Lymphoma
    • 9.4.1. Hodgkin Lymphoma
    • 9.4.2. Non Hodgkin Lymphoma
  • 9.5. Melanoma

10. Immuno-Oncology Service Market, by End User

  • 10.1. Hospitals
    • 10.1.1. Community Hospitals
    • 10.1.2. University Hospitals
  • 10.2. Research Institutes
    • 10.2.1. Academic Institutes
    • 10.2.2. Government Institutes
  • 10.3. Specialty Clinics
    • 10.3.1. Day Care Centers
    • 10.3.2. Oncology Clinics

11. Immuno-Oncology Service Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Distributor Networks
    • 11.2.1. Medical Device Distributors
    • 11.2.2. Pharma Distributors
  • 11.3. Online Platforms
    • 11.3.1. Company Websites
    • 11.3.2. Third Party Platforms

12. Immuno-Oncology Service Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Immuno-Oncology Service Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Immuno-Oncology Service Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Immuno-Oncology Service Market

16. China Immuno-Oncology Service Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Catalent, Inc.
  • 17.6. Charles River Laboratories International, Inc.
  • 17.7. Evotec SE
  • 17.8. ICON plc
  • 17.9. IQVIA Holdings Inc.
  • 17.10. Laboratory Corporation of America Holdings
  • 17.11. Novartis AG
  • 17.12. Pfizer Inc.
  • 17.13. SGS SA
  • 17.14. Syneos Health, Inc.
  • 17.15. Takeda Pharmaceutical Company Limited
  • 17.16. Thermo Fisher Scientific Inc.
  • 17.17. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES IMMUNO-ONCOLOGY SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CELL BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CELL BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CELL BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY GENETIC VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY GENETIC VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY GENETIC VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY PEPTIDE BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY PEPTIDE BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY PEPTIDE BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY BCMA DIRECTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY BCMA DIRECTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY BCMA DIRECTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CD19 DIRECTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CD19 DIRECTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CD19 DIRECTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHIMERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY FULLY HUMAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY FULLY HUMAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HUMANIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HODGKIN LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HODGKIN LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY UNIVERSITY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY UNIVERSITY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY UNIVERSITY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY GOVERNMENT INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY GOVERNMENT INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY GOVERNMENT INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DAY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DAY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DAY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MEDICAL DEVICE DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MEDICAL DEVICE DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MEDICAL DEVICE DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY PHARMA DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY PHARMA DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY PHARMA DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COMPANY WEBSITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COMPANY WEBSITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COMPANY WEBSITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THIRD PARTY PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THIRD PARTY PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THIRD PARTY PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 269. GLOBAL IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 286. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 287. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 289. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 290. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 291. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 292. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 293. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 294. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 295. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 297. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 298. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 299. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 300. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY DISTRIBUTOR NETWORKS, 2018-2032 (USD MILLION)
  • TABLE 301. GCC IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY ONLINE PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CAR-T THERAPY, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION IMMUNO-ONCOLOGY SERVICE MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION IMMUNO-ONCOLOGY